share_log

Novavax | 4: Statement of changes in beneficial ownership of securities-Director MOTT DAVID M

Novavax | 4: Statement of changes in beneficial ownership of securities-Director MOTT DAVID M

诺瓦瓦克斯医药 | 4：持股变动声明-董事 MOTT DAVID M
美股sec公告 ·  06/14 16:29
Moomoo AI 已提取核心信息
David M. Mott, reported a completed transaction involving the acquisition of 6,670 shares of Novavax Inc (NVAX) common stock on June 12, 2024. The shares were acquired at a price of $0.00, indicating the transaction was likely an exercise or conversion of derivative securities. Following this transaction, Mott's direct holdings in Novavax increased to a total of 50,470 shares. The nature of the transaction suggests an investment in the company's growth and potential, as Mott increases his stake in the pharmaceutical firm.
David M. Mott, reported a completed transaction involving the acquisition of 6,670 shares of Novavax Inc (NVAX) common stock on June 12, 2024. The shares were acquired at a price of $0.00, indicating the transaction was likely an exercise or conversion of derivative securities. Following this transaction, Mott's direct holdings in Novavax increased to a total of 50,470 shares. The nature of the transaction suggests an investment in the company's growth and potential, as Mott increases his stake in the pharmaceutical firm.
大卫·莫特（David M. Mott）于2024年6月12日完成了对诺瓦瓦克斯医药（Novavax Inc (NVAX)）普通股的6,670股收购交易。这些股票的购买价格为0.00美元，表明该交易很可能是衍生证券的行权或转换。此次交易后，莫特在诺瓦瓦克斯医药的直接持股总数增加到50,470股。交易的性质表明，莫特在这个药品公司的增持是基于该公司的增长和潜力。
大卫·莫特（David M. Mott）于2024年6月12日完成了对诺瓦瓦克斯医药（Novavax Inc (NVAX)）普通股的6,670股收购交易。这些股票的购买价格为0.00美元，表明该交易很可能是衍生证券的行权或转换。此次交易后，莫特在诺瓦瓦克斯医药的直接持股总数增加到50,470股。交易的性质表明，莫特在这个药品公司的增持是基于该公司的增长和潜力。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息